Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target Lowered to $41.00 at Piper Sandler

Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) had its price objective lowered by Piper Sandler from $45.00 to $41.00 in a research note released on Wednesday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the specialty pharmaceutical company’s stock. Separately, StockNews.com upgraded shares of Supernus Pharmaceuticals from a hold rating to a buy […]

Leave a Reply

Your email address will not be published.

Previous post VictoryShares Emerging Markets Value Momentum ETF (NASDAQ:UEVM) Short Interest Up 1,300.0% in February
Next post U Power Limited (NASDAQ:UCAR) Short Interest Up 1,078.8% in February